Major pharmaceutical companies will be free to gouge patients on the costs for vital prescription drugs, under the health care plans currently under consideration by Donald Trump and congressional Republicans.
Trump’s transition health care agenda makes no mention of efforts to control drug prices, yet it does mention bans on abortion coverage and efforts to privatize Medicare and Medicaid.
Allies of the drug industry have taken key roles in the incoming administration, including Mike Pence, who will serve as Trump’s vice president. Drug industry lobbyists are also involved in the Trump transition team.
Infamous pharmaceutical executive Martin Shkreli, who profited from artificially inflating the price of the HIV/AIDS drug Daraprim, was a prominent supporter of Trump’s during the presidential campaign.